Residual inflammatory risk post STEMI: high prevalence despite LDL-C control and association with other secondary prevention targets - Summary - MDSpire
Advertisement
Residual inflammatory risk post STEMI: high prevalence despite LDL-C control and association with other secondary prevention targets
To evaluate the prevalence of residual inflammatory risk using hs-CRP as a marker and its association with achieving specific guideline-recommended secondary prevention targets, including waist circumference, LDL-C, and triglycerides, following primary percutaneous coronary intervention (pPCI) in STEMI patients.
Key Findings:
The median hs-CRP level was 2.7 mg/L, with 44.6% of patients having levels >3 mg/L, indicating a significant prevalence of residual inflammatory risk.
Achieving targets for waist circumference, LDL-C (<55 mg/dL), and triglycerides (<150 mg/dL), as well as adherence to statin and ACEI/ARB therapy, were associated with lower odds of elevated hs-CRP, suggesting effective management strategies.
29.8% of patients with LDL-C < 55 mg/dL still exhibited elevated hs-CRP, indicating persistent inflammatory risk that may require additional intervention.
Interpretation:
Residual inflammatory risk is prevalent after STEMI, even with optimal LDL-C control. Comprehensive secondary prevention correlates with lower hs-CRP levels.
Limitations:
The study is retrospective and may be subject to selection bias, potentially affecting the generalizability of the findings.
Data on some secondary prevention metrics, such as smoking cessation and BMI, were not uniformly available, which may limit the comprehensiveness of the analysis.
Conclusion:
Residual inflammatory risk remains a significant concern post-STEMI, highlighting the need for strategies targeting inflammation alongside traditional risk factor management to improve patient outcomes.
